"How paediatric start-ups can navigate the current funding landscape?"
How paediatric start-ups can navigate the current funding landscape? Don't miss this training capsule on investment strategies in paediatrics.
i4KIDS Training Capsule that dives into funding options and investment strategies for paediatric projects, highlighting successful models (private and public) and uncovering exciting opportunities.
Panel of Experts:
- David Cole, MBA – Director and CCHO, TOO Futures Ltd (UK)
- John Parker – Founder and Managing Partner, Springhood Ventures (US)
- Kerstin Papenfuss, PhD MBA – Director Pharma at Deep Science Ventures (UK)
- Marc Ramis Castelltort – Managing Partner, Montana Impact Fund (Spain)
The discussion leverages insights from the i4KIDSEUROPE report: “Europe Paediatric Innovation Situation Report and Needs Analysis” to offer guidance for founders and start-ups navigating the paediatric funding landscape.
Related News
Featured
i4KIDS has completed its first season of collaboration with RNE's Cuídate programme, featuring nine episodes focused on paediatric and foetal health innovation. The series brought together healthcare professionals, researchers and innovators to discuss advances in areas such as rare diseases, paediatric haematology, prematurity, neurodevelopment, congenital heart disease and paediatric palliative care.
Featured
i4KIDS is reinforcing its commitment to innovation in paediatric, fetal and maternal health by collaborating in two strategic initiatives currently open for applications: CRAASH Barcelona 2026 and DKV Challenge 2026. Both programmes offer new opportunities for startups and innovative projects seeking to accelerate the development, validation and adoption of solutions with an impact on maternal and child health.
Uncategorized
i4KIDS and Catalonia.Health brought together startup leaders, researchers and healthcare professionals to discuss funding, regulatory strategy and international growth. The session featured Gisela Lorente (Aptadel Therapeutics), Marc Martinell (Minoryx Therapeutics) and Stefanos Theoharis (OneChain Immunotherapeutics), highlighting Barcelona's growing role as a leading hub for paediatric health innovation.